Company
Headquarters: Tokyo, Japan
Employees: 1,558
¥116.64 Billion
JPY as of July 1, 2024
US$722.4 Million
Company | Market Cap (USD) |
---|---|
Lilly | $808.65 B |
Novo Nordisk | $622.07 B |
UnitedHealth Group | $450.89 B |
Johnson & Johnson | $350.63 B |
Merck | $318.75 B |
Mochida Pharmaceutical Co., Ltd. produces and sells pharmaceuticals, skincare products, and diagnostics solutions in Japan. The company provides cardiovascular, analgesic, gastrointestinal, neurological, anti-infective, antidiabetics, and anticancer products, as well as hormone and biological preparations, and biosimilars; diagnostic reagents, such as reagents for fertility/infertility and other reagents; and face and body care, hair care, and skincare products, as well as dermatology, psychiatry, obstetrics, and gynecology products. It also developing drugs for the treatment of intractable diseases. The company has collaboration agreements with Amarin Corporation plc for the development and commercialization of ethyl icosapentate products; and Gene Techno Science Co., Ltd. to develop new regenerative medicine for the treatment of digestive rare and intractable diseases, such as congenital isolated hypoganglionosis. Mochida Pharmaceutical Co., Ltd. was founded in 1913 and is headquartered in Tokyo, Japan.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Mochida Pharmaceutical Co. Ltd has the following listings and related stock indices.
Stock: JPX: 4534 wb_incandescent
Stock: FSX: MFY wb_incandescent